Prognostic evaluation of relapse based on squamous cell carcinoma antigen, CXCR2, and CD44V6 blood levels in patients with Stage I–II squamous cell lung cancer

A. Tahanovich, M. Kauhanka, Zhanna A. Rutkovskaya, Ekaterina A. Khotko, O. V. Gotko, Violetta I . Prokhorova
{"title":"Prognostic evaluation of relapse based on squamous cell carcinoma antigen, CXCR2, and CD44V6 blood levels in patients with Stage I–II squamous cell lung cancer","authors":"A. Tahanovich, M. Kauhanka, Zhanna A. Rutkovskaya, Ekaterina A. Khotko, O. V. Gotko, Violetta I . Prokhorova","doi":"10.36922/gtm.2209","DOIUrl":null,"url":null,"abstract":"Lung cancer, the leading cause of cancer-related mortality, predominantly exists as non-small cell lung cancer, accounting for approximately 85% of cases and comprising adenocarcinoma, squamous cell carcinoma (SCC), and large cell carcinoma as the three most prevalent histological subtypes. This study focused on investigating pre- and post-operative concentrations of SCC antigen in blood serum, as well as the percentage of CXCR2-containing lymphocytes and CD44v6-containing monocytes in blood cell populations among patients with Stages I–II squamous cell lung cancer (SCLC) within 1 year after tumor resection. The primary objective was to assess their potential for predicting relapse. The study cohort comprised 57 patients (32 men and 25 women) with newly diagnosed squamous cell lung cancer (21 at stage I and 36 at stage II). Following tumor resection, categorized as R0 in terms of surgical intervention, all parameters were examined before surgery and at 3 weeks, 3 months, and 6 months postoperatively. Analysis revealed that the probability of relapse could be accurately predicted, ranging from 68.4% to 89.5%, based on differences in SCC antigen concentration, the percentage of lymphocytes with CXCR2, and monocytes with the CD44v6 receptor during various post-operative intervals. Subsequent regression analysis and the formulation of a combined model incorporating the above-mentioned parameters led to an enhanced predictive value for tumor recurrence, reaching 96.5% accuracy (with specificity at 95.6% and sensitivity at 100%). These results indicate the potential utility of the combined model as an additional marker for predicting postoperative relapse in patients with Stage I–II SCLC.","PeriodicalId":73176,"journal":{"name":"Global translational medicine","volume":"145 3‐9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global translational medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36922/gtm.2209","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Lung cancer, the leading cause of cancer-related mortality, predominantly exists as non-small cell lung cancer, accounting for approximately 85% of cases and comprising adenocarcinoma, squamous cell carcinoma (SCC), and large cell carcinoma as the three most prevalent histological subtypes. This study focused on investigating pre- and post-operative concentrations of SCC antigen in blood serum, as well as the percentage of CXCR2-containing lymphocytes and CD44v6-containing monocytes in blood cell populations among patients with Stages I–II squamous cell lung cancer (SCLC) within 1 year after tumor resection. The primary objective was to assess their potential for predicting relapse. The study cohort comprised 57 patients (32 men and 25 women) with newly diagnosed squamous cell lung cancer (21 at stage I and 36 at stage II). Following tumor resection, categorized as R0 in terms of surgical intervention, all parameters were examined before surgery and at 3 weeks, 3 months, and 6 months postoperatively. Analysis revealed that the probability of relapse could be accurately predicted, ranging from 68.4% to 89.5%, based on differences in SCC antigen concentration, the percentage of lymphocytes with CXCR2, and monocytes with the CD44v6 receptor during various post-operative intervals. Subsequent regression analysis and the formulation of a combined model incorporating the above-mentioned parameters led to an enhanced predictive value for tumor recurrence, reaching 96.5% accuracy (with specificity at 95.6% and sensitivity at 100%). These results indicate the potential utility of the combined model as an additional marker for predicting postoperative relapse in patients with Stage I–II SCLC.
基于 I-II 期鳞状细胞肺癌患者血液中鳞状细胞癌抗原、CXCR2 和 CD44V6 水平的复发预后评估
肺癌是癌症相关死亡的主要原因,主要表现为非小细胞肺癌,约占病例总数的 85%,包括腺癌、鳞状细胞癌(SCC)和大细胞癌这三种最常见的组织学亚型。这项研究的重点是调查 I-II 期鳞状细胞肺癌(SCLC)患者在肿瘤切除术后一年内血清中 SCC 抗原的术前和术后浓度,以及血细胞群中含有 CXCR2 的淋巴细胞和含有 CD44v6 的单核细胞的百分比。主要目的是评估它们预测复发的潜力。研究队列包括 57 名新确诊的鳞状细胞肺癌患者(32 名男性和 25 名女性)(21 名 I 期患者和 36 名 II 期患者)。肿瘤切除后,手术干预被归类为 R0,所有参数在术前、术后 3 周、3 个月和 6 个月进行了检查。分析表明,根据术后不同时间段内 SCC 抗原浓度、含 CXCR2 的淋巴细胞和含 CD44v6 受体的单核细胞百分比的差异,可以准确预测复发的概率,范围从 68.4% 到 89.5%。随后的回归分析和结合上述参数的综合模型使肿瘤复发的预测值得到了提高,准确率达到了 96.5%(特异性为 95.6%,敏感性为 100%)。这些结果表明,该组合模型可作为预测 I-II 期 SCLC 患者术后复发的额外指标。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信